Modality
Radioligand
MOA
TNFi
Target
Tau
Pathway
RAS/MAPK
Hemophilia A
Development Pipeline
Preclinical
~Nov 2014
→ ~Feb 2016
Phase 1
~May 2016
→ ~Aug 2017
Phase 2
~Nov 2017
→ ~Feb 2019
Phase 3
~May 2019
→ ~Aug 2020
NDA/BLA
Nov 2020
→ Dec 2031
NDA/BLACurrent
NCT06847866
2,981 pts·Hemophilia A
2023-02→2031-12·Not yet recruiting
NCT03572481
514 pts·Hemophilia A
2020-11→TBD·Completed
3,495 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-12-075.7y awayPh3 Readout· Hemophilia A
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
NDA/BLA
Complet…
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2031-12-07 · 5.7y away
Hemophilia A
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06847866 | NDA/BLA | Hemophilia A | Not yet recr... | 2981 | ORR |
| NCT03572481 | NDA/BLA | Hemophilia A | Completed | 514 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D | |
| 369-789 | Hansoh Pharma | Phase 3 | PI3Kα | |
| Rimatinib | Ventyx Bio | Phase 1 | CD20 | |
| Talatuximab | Protagonist | Phase 2 | B7-H3 | |
| TER-5062 | Terns | Phase 2/3 | Tau | |
| Tirainavolisib | Chugai | Approved | DLL3 |